101 related articles for article (PubMed ID: 16847412)
1. Uridine supplementation enhances hepatic mitochondrial function in thymidine-analogue treated HIV-infected patients.
Banasch M; Goetze O; Knyhala K; Potthoff A; Schlottmann R; Kwiatek MA; Bulut K; Schmitz F; Schmidt WE; Brockmeyer NH
AIDS; 2006 Jul; 20(11):1554-6. PubMed ID: 16847412
[TBL] [Abstract][Full Text] [Related]
2. [13C]Methionine breath test: a novel method to detect antiretroviral drug-related mitochondrial toxicity.
Milazzo L; Piazza M; Sangaletti O; Gatti N; Cappelletti A; Adorni F; Antinori S; Galli M; Moroni M; Riva A
J Antimicrob Chemother; 2005 Jan; 55(1):84-9. PubMed ID: 15590719
[TBL] [Abstract][Full Text] [Related]
3. Uridine supplementation for the treatment of antiretroviral therapy-associated lipoatrophy: a randomized, double-blind, placebo-controlled trial.
Sutinen J; Walker UA; Sevastianova K; Klinker H; Häkkinen AM; Ristola M; Yki-Järvinen H
Antivir Ther; 2007; 12(1):97-105. PubMed ID: 17503753
[TBL] [Abstract][Full Text] [Related]
4. No significant effect of uridine or pravastatin treatment for HIV lipoatrophy in men who have ceased thymidine analogue nucleoside reverse transcriptase inhibitor therapy: a randomized trial.
Calmy A; Bloch M; Wand H; Delhumeau C; Finlayson R; Rafferty M; Norris R; Hirschel B; Cooper DA; Carr A;
HIV Med; 2010 Sep; 11(8):493-501. PubMed ID: 20236365
[TBL] [Abstract][Full Text] [Related]
5. Mitochondrial function, inflammation, fat and bone in HIV lipoatrophy: randomized study of uridine supplementation or switch to tenofovir.
McComsey GA; O'Riordan M; Choi J; Libutti D; Rowe D; Storer N; Harrill D; Gerschenson M
Antivir Ther; 2012; 17(2):347-53. PubMed ID: 22293126
[TBL] [Abstract][Full Text] [Related]
6. Uridine in the prevention and treatment of NRTI-related mitochondrial toxicity.
Walker UA; Venhoff N
Antivir Ther; 2005; 10 Suppl 2():M117-23. PubMed ID: 16152713
[TBL] [Abstract][Full Text] [Related]
7. Gene expression and immunohistochemistry in adipose tissue of HIV type 1-infected patients with nucleoside analogue reverse-transcriptase inhibitor-associated lipoatrophy.
Sievers M; Walker UA; Sevastianova K; Setzer B; Wågsäter D; Eriksson P; Yki-Järvinen H; Sutinen J
J Infect Dis; 2009 Jul; 200(2):252-62. PubMed ID: 19519254
[TBL] [Abstract][Full Text] [Related]
8. Disease- and treatment-related predictors of hepatic mitochondrial dysfunction in chronic HIV infection assessed by non-invasive (13)C-methionine breath test diagnostic.
Banasch M; Knyhala K; Kollar S; Serova K; Potthoff A; Schlottmann R; Schmidt WE; Brockmeyer NH; Goetze O
Eur J Med Res; 2008 Sep; 13(9):401-8. PubMed ID: 18948231
[TBL] [Abstract][Full Text] [Related]
9. Uridine supplementation in HIV lipoatrophy: pilot trial on safety and effect on mitochondrial indices.
McComsey GA; O'Riordan M; Setzer B; Lebrecht D; Baron E; Walker UA
Eur J Clin Nutr; 2008 Aug; 62(8):1031-7. PubMed ID: 17538545
[TBL] [Abstract][Full Text] [Related]
10. Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA).
Negredo E; Miró O; Rodríguez-Santiago B; Garrabou G; Estany C; Masabeu A; Force L; Barrufet P; Cucurull J; Domingo P; Alonso-Villaverde C; Bonjoch A; Morén C; Pérez-Alvarez N; Clotet B;
Clin Infect Dis; 2009 Sep; 49(6):892-900. PubMed ID: 19663689
[TBL] [Abstract][Full Text] [Related]
11. Nucleoside analogues toxicities related to mitochondrial dysfunction: focus on HIV-infected children.
Viganò A; Giacomet V
Antivir Ther; 2005; 10 Suppl 2():M53-64. PubMed ID: 16152706
[No Abstract] [Full Text] [Related]
12. Mitochondrial damage in adipose tissue of untreated HIV-infected patients.
Garrabou G; López S; Morén C; Martínez E; Fontdevila J; Cardellach F; Gatell JM; Miró O
AIDS; 2011 Jan; 25(2):165-70. PubMed ID: 21150553
[TBL] [Abstract][Full Text] [Related]
13. Effect of the substitution of one nucleoside analogue by one non-nucleoside reverse transcriptase inhibitor over mitochondrial DNA levels.
De Felipe B; Blanco A; Soriano-Sarabia N; Muñoz-Fernández MA; Genebat M; Vallejo A; Leal M
Infection; 2008 Jun; 36(3):266-70. PubMed ID: 18463785
[TBL] [Abstract][Full Text] [Related]
14. Uridine supplementation antagonizes zidovudine-induced mitochondrial myopathy and hyperlactatemia in mice.
Lebrecht D; Deveaud C; Beauvoit B; Bonnet J; Kirschner J; Walker UA
Arthritis Rheum; 2008 Jan; 58(1):318-26. PubMed ID: 18163507
[TBL] [Abstract][Full Text] [Related]
15. Pathogenesis and treatment of lipodystrophy: what clinicians need to know.
Sattler FR
Top HIV Med; 2008; 16(4):127-33. PubMed ID: 18838747
[TBL] [Abstract][Full Text] [Related]
16. Beneficial effects of oral uridine in mitochondrial toxicity.
Walker UA; Langmann P; Miehle N; Zilly M; Klinker H; Petschner F
AIDS; 2004 Apr; 18(7):1085-6. PubMed ID: 15096820
[No Abstract] [Full Text] [Related]
17. Pathogenesis and management of lipoatrophy.
Tungsiripat M; McComsey G
Curr HIV/AIDS Rep; 2008 May; 5(2):55-63. PubMed ID: 18510890
[TBL] [Abstract][Full Text] [Related]
18. Editorial response: hyperlactatemia and hepatic steatosis as features of mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors.
Brinkman K
Clin Infect Dis; 2000 Jul; 31(1):167-9. PubMed ID: 10913416
[No Abstract] [Full Text] [Related]
19. Liver function as assessed by breath tests in patients with hepatocellular carcinoma.
Palmieri VO; Grattagliano I; Minerva F; Pollice S; Palasciano G; Portincasa P
J Surg Res; 2009 Dec; 157(2):199-207. PubMed ID: 19540521
[TBL] [Abstract][Full Text] [Related]
20. Uridine supplementation antagonizes zalcitabine-induced microvesicular steatohepatitis in mice.
Lebrecht D; Vargas-Infante YA; Setzer B; Kirschner J; Walker UA
Hepatology; 2007 Jan; 45(1):72-9. PubMed ID: 17187420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
